
Pharmaceutical R&D and Sales

Pharmaceutical Manufacturer
Drug Developer

Biopharmaceutical Manufacturer
LONDON and BELGRADE, Serbia, April 1, 2021 /PRNewswire/ --Frontier PharmaBaystone Group and Teva today announced the completion of the acquisition of a subsidiary under Teva PharmaceuticalsZdravlje A.Dacquisition. Zdravlje currently supplies high-quality pharmaceutical products to more than 35 international markets, including those in Western and Eastern Europe, the United Kingdom, Asia-Pacific, Sub-Saharan Africa, and Latin America.
“We are delighted to have completed this transaction and to support Zdravlje in becoming a leading independent pharmaceutical company. We look forward to collaborating with Zdravlje’s talented and exceptional team to further develop the company into a leading international pharmaceutical enterprise,” said M. Levent Selamoglu, Chairman of Frontier Pharma.
Zdravlje, established in 1953, has a 67-year history of manufacturing and supplying high-quality pharmaceutical products. The company currently employs over 250 people and produces a wide range of oral solid and liquid formulations for the treatment of various serious and chronic conditions, including cardiovascular, central nervous system, and respiratory diseases. Zdravlje also offers a portfolio of complementary branded generic products, which form the foundation of an independent commercial strategy under the “Zdravlje” brand.
“We look forward to leveraging Zdravlje’s strong track record as a premier global supplier to build an industry-leading, fully integrated pharmaceutical platform,” said Kiren Naidoo, Chief Executive Officer of Frontier Pharma.
“This marks a key milestone in Zdravlje’s history; we are pleased to continue delivering high-quality products to more than 35 countries worldwide, thereby further driving the success we have achieved in the pharmaceutical industry and supporting the local communities where we have successfully operated for over 67 years,” said Bojan Jovic, General Manager of Zdravlje.